Skip to main content

Vision

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

VIVUS
VIVUSCA - Campbell
1 program
1
Stendra 200 mgPhase 41 trial
Active Trials
NCT02033200Completed80Est. Jan 2014
Alcon
AlconFORT WORTH, TX
1 program
Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182N/A1 trial
Active Trials
NCT00713076Completed30

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VIVUSStendra 200 mg
AlconPolyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182

Clinical Trials (2)

Total enrollment: 110 patients across 2 trials

NCT02033200VIVUSStendra 200 mg

Safety Study Looking at the Effects of Stendra on Vision

Start: Jan 2014Est. completion: Jan 201480 patients
Phase 4Completed
NCT00713076AlconPolyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182

Wettability of Contact Lenses With a Multi-Purpose Solution

Start: Oct 200730 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.